Heart failure with preserved ejection fraction after left‐sided valve surgery: prevalent and relevant

Kammerlander, Andreas A.; Nitsche, Christian; Donà, Carolina; Koschutnik, Matthias; Mascherbauer, Katharina; Schönbauer, Robert; Zafar, Amna; Winter, Max‐Paul; Bartko, Philipp E.; Hengstenberg, Christian; Mascherbauer, Julia

doi:10.1002/ejhf.2345

Cited by 8 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk ratio for those with severe LVH at 1.7 7 was almost identical to that reported by Kammerlander et al . for their ‘HFpEF’ phenotype, 1 so in essence their study reinforces the known prognostic significance of hypertension, LVH, atrial fibrillation, LA volume, and natriuretic peptide levels after valve surgery.…”

Section: Left Ventricular Hypertrophy As a Risk Factor After Valve In...mentioning

confidence: 55%

“…Kammerlander et al 1 report that two thirds of their patients attending for follow-up on average 50 months after surgery for aortic or mitral valve disease, fulfilled diagnostic criteria for heart failure with preserved ejection fraction (HFpEF). More than half of the patients were in atrial fibrillation and their natriuretic peptide levels were very high, exceeding levels usually observed in patients with HFpEF alone.…”

Section: This Article Refers To 'Heart Failure With Preserved Ejectio...mentioning

confidence: 99%

“…In the study by Kammerlander et al, overall mortality after 83 ± 39 months was 34%. 1 As well as individual treatment directed to the primary target of hypertension with LVH, there is a need for more evidence to guide therapeutic decisions. Since most patients are now enrolled in registries, there is scope for large registry-based randomized trials.…”

Section: Priorities For Managing Patients After Valve Replacementmentioning

confidence: 99%

“…Kammerlander et al 1 . report that two thirds of their patients attending for follow‐up on average 50 months after surgery for aortic or mitral valve disease, fulfilled diagnostic criteria for heart failure with preserved ejection fraction (HFpEF).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility

Fraser

Szymański

2021

European J of Heart Fail

View full text Add to dashboard Cite

Section: Left Ventricular Hypertrophy As a Risk Factor After Valve In...mentioning

confidence: 55%

Section: This Article Refers To 'Heart Failure With Preserved Ejectio...mentioning

confidence: 99%

Section: Priorities For Managing Patients After Valve Replacementmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility

Fraser

Szymański

2021

European J of Heart Fail

View full text Add to dashboard Cite

“…Heart failure with preserved ejection fraction is a heterogeneous syndrome with multiple aetiologies and phenotypes. [13][14][15] Kammerlander et al 16 investigated the prevalence of HFpEF following left-sided valve repair. Out of 973 patients included, 673 underwent surgery and 300, with HFpEF, did not (control group).…”

Section: Valvular Heart Diseasementioning

confidence: 99%

December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models

Tomasoni

Adamo

Metra

2021

European J of Heart Fail

View full text Add to dashboard Cite

Heart failure: an update from the last years and a look at the near future

et al. 2022

View full text Add to dashboard Cite

In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst verciguat is becoming available across several countries, omecamtiv mecarbil is waiting to be released for clinical use. Concurrent use of potassium-lowering agents may counteract hyperkalaemia and facilitate renin-angiotensin-aldosterone system inhibitor implementations. The results of the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) trial were confirmed by the Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER) trial, and we now have, for the first time, evidence for treatment of also patients with HF with preserved ejection fraction. In a pre-specified meta-analysis of major randomized controlled trials, sodium-glucose co-transporter-2 inhibitors reduced all-cause mortality, cardiovascular (CV) mortality, and HF hospitalization in the patients with HF regardless of left ventricular ejection fraction. Other steps forward have occurred in the treatment of decompensated HF. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload (ADVOR) trial showed that the addition of intravenous acetazolamide to loop diuretics leads to greater decongestion vs. placebo. The addition of hydrochlorothiazide to loop diuretics was evaluated in the CLOROTIC trial. Torasemide did not change outcomes, compared with furosemide, in TRANSFORM-HF. Ferric derisomaltose had an effect on the primary outcome of CV mortality or HF rehospitalizations in IRONMAN (rate ratio 0.82; 95% confidence interval 0.66-1.02; P = 0.070). Further options for the treatment of HF, including device therapies, cardiac contractility modulation, and percutaneous treatment of valvulopathies, are summarized in this article.

show abstract

Heart failure with preserved ejection fraction after left‐sided valve surgery: prevalent and relevant

Abstract: To investigate the epidemiological and prognostic relationship between heart failure with preserved ejection fraction (HFpEF) and left-sided valve surgery using all-cause mortality as a primary endpoint.

Cited by 8 publications

References 30 publications

Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility

Heart valve disease, left ventricular hypertrophy, and heart failure: a lifelong relationship and continuing clinical responsibility

December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models

Heart failure: an update from the last years and a look at the near future

Contact Info

Product

Resources

About